AnteoTech Ltd (AU:ADO)
ASX:ADO
Want to see AU:ADO full AI Analyst Report?
ADO Stock Chart & Stats
AU$0.02
>-AU$0.01(-5.00%)
At close: 4:00 PM EST
AU$0.02
>-AU$0.01(-5.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.05
Previous CloseN/A
Volume1.67M
Average Volume (3M)1.47M
Market Cap
AU$97.79M
Enterprise ValueAU$114.39M
Total Cash (Recent Filing)AU$1.44M
Total Debt (Recent Filing)AU$2.85M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding3,259,767,300
10 Day Avg. Volume1,501,441
30 Day Avg. Volume1,471,917
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)10.79
Price to Sales (P/S)35.07
P/FCF Ratio-5.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$1.70M
Bulls Say, Bears Say
Bulls Say
Proprietary Surface Functionalisation TechnologyAnteoTech’s proprietary surface functionalisation platform is a durable competitive asset across diagnostics and energy. It supports differentiated product inputs, creates technical barriers to entry, and enables long development/qualification cycles that foster sticky licensing and partnership revenue over months to years.
Diversified Commercial Revenue ModelMultiple monetisation paths (product sales, licensing/royalties, paid development, grants) reduce reliance on a single revenue source. This structural diversity supports resilience through partner validation cycles and creates recurring and milestone-driven cash opportunities as technologies scale.
Manageable Balance Sheet LeverageA moderate debt-to-equity ratio of 0.62 indicates limited financial leverage relative to riskier peers. This structural capacity reduces immediate refinancing pressure, providing flexibility to fund R&D, scale manufacturing or absorb cyclical setbacks without acute solvency stress over the next several months.
Bears Say
Persistent Losses And Negative MarginsConsistent negative net, EBIT and EBITDA margins indicate the business is not yet profitable. Ongoing losses constrain reinvestment, lengthen the path to self-funded growth, and raise execution risk as management must secure external capital to sustain operations and commercialisation efforts.
Negative Operating And Free Cash FlowsNegative operating and free cash flows represent structural cash burn that undermines financial flexibility. Even with a modest improvement in FCF trend, continued outflows increase reliance on external funding, elevating dilution and execution risk for product qualification and scale-up over the medium term.
Revenue Volatility And Recent Steep DeclineSharp revenue swings and a recent steep decline indicate dependence on episodic contracts or milestone timing. Such structural volatility complicates forecasting, weakens recurring revenue profile, and slows the ability to credibly scale manufacturing or commercial operations over the coming months.
AnteoTech Ltd News
ADO FAQ
What was AnteoTech Ltd’s price range in the past 12 months?
AnteoTech Ltd lowest share price was <AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is AnteoTech Ltd’s market cap?
AnteoTech Ltd’s market cap is AU$97.79M.
When is AnteoTech Ltd’s upcoming earnings report date?
AnteoTech Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 87 days.
How were AnteoTech Ltd’s earnings last quarter?
AnteoTech Ltd released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is AnteoTech Ltd overvalued?
According to Wall Street analysts AnteoTech Ltd’s price is currently Overvalued.
Does AnteoTech Ltd pay dividends?
AnteoTech Ltd does not currently pay dividends.
What is AnteoTech Ltd’s EPS estimate?
AnteoTech Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AnteoTech Ltd have?
AnteoTech Ltd has 3,259,767,300 shares outstanding.
What happened to AnteoTech Ltd’s price movement after its last earnings report?
AnteoTech Ltd reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of AnteoTech Ltd?
Currently, no hedge funds are holding shares in AU:ADO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnteoTech Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ADO Sentiment 98%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$86.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
-142.30%
Trailing 12-Months
Asset Growth
-58.00%
Trailing 12-Months
Company Description
AnteoTech Ltd
AnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia. Its products include AnteoBind ready-to-use kits to streamline and enhance the conjugation process; AnteoX, an additive that reinforces battery binders helping maximize performance of silicon containing anodes; EuGeni, a COVID-19 antigen rapid test; and AnteoRelease and AnteoCoat. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
Avecho Biotechnology Limited
―
Proteomics International Laboratories Ltd.
―
Options Prices
Currently, No data available
---